Work

Transforming cancer care in India - Steps in the right direction

Year: 2024

Type: article

Abstract: Cancer remains a formidable public health challenge, with the financial burden of treatment placing many families under severe economic distress, particularly in low-to middle-income countries like India.Recognizing this, the Indian Union Budget for 2024-2025 introduced customs duty exemptions and GST reduction (from 12% to 5%) on three high-impact cancer drugs: trastuzumab deruxtecan (TDxd), osimertinib, and durvalumab.This policy change marks a critical step toward making life-saving therapies more accessible and affordable, potentially significantly improving patient outcomes.

Source: International Journal of Molecular and Immuno Oncology

DOI: 10.25259/ijmio_29_2024

Authors: Karan Sood, Prashant Mehta

Institution: Amrita Institute of Medical Sciences and Research Centre

Language: English

Topic: Economic and Financial Impacts of Cancer

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W4404587437